Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ALPP CAR-T cells (TCRCure Biotech)
- Development stage
- Unknown
- Lead developer
- TCRCure Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-ALPP CAR-T cells (TC-A101) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by TCRCure Biopharma for the treatment of advanced solid tumors that express placental alkaline phosphatase (ALPP). ALPP is a tumor-associated antigen and glycosylphosphatidylinositol (GPI)-anchored protein that is frequently overexpressed in various malignancies, including ovarian, endometrial, and testicular cancers, while maintaining very low expression in healthy adult tissues. The therapy involves the genetic modification of a patient's own T cells using a retroviral vector to express a CAR specific for ALPP. Following lymphodepleting chemotherapy with fludarabine and cyclophosphamide, the engineered T cells are infused back into the patient to recognize and eliminate ALPP-positive tumor cells. It is currently being evaluated in Phase 1 clinical trials (such as NCT04627740) to assess safety, tolerability, and preliminary clinical efficacy.
- Other names
- alkaline phosphatase, placental-targeted CAR-T cellsALPP CAR-T cells
02
Targets
ALPP (Alkaline phosphatase, placental type)
Beyond the preview
Go deeper on anti-ALPP CAR-T cells (TCRCure Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ALPP CAR-T cells (TCRCure Biotech).